NEW YORK, Oct. 24 - Abbott Laboratories has agreed to acquire Vysis in a stock deal worth about $355 million in an attempt to buttress its position in the DNA-based diagnostic market, the drug giant announced on Wednesday.

Abbott will pay $30.50 per share for Vysis, which is a 33 percent premium on Vysis shares, the company said. Shares in the Downers Grove, Illinois-based company closed at $23 on the Nasdaq on Tuesday.

Vysis manufactures and markets two tests that detect certain genetic markers for breast and bladder cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.